Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
238 hedge funds and large institutions have $4.78B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2020 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 79 increasing their positions, 89 reducing their positions, and 26 closing their positions.
92% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 26
61% more call options, than puts
Call options by funds: $282M | Put options by funds: $176M
22% more capital invested
Capital invested by funds: $3.9B → $4.78B (+$874M)
11% more funds holding
Funds holding: 215 → 238 (+23)
8% less funds holding in top 10
Funds holding in top 10: 13 → 12 (-1)
11% less repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 89
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$114M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$25.7M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$17.1M |
| 4 |
ClearBridge Investments
New York
|
+$13.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$67.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$63.9M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$38.9M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$35.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$34.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
251
Squarepoint
New York
| – | -$895K | -13,774 | Closed |
|
|
SSA
252
Schonfeld Strategic Advisors
New York
| – | -$879K | -13,525 | Closed |
|
253
Jennison Associates
New York
| – | -$618K | -9,503 | Closed |
|
|
CIS
254
Capital International Sarl
Los Angeles,
California
| – | -$604K | -9,286 | Closed |
|
|
NAM
255
Nexpoint Asset Management
Dallas,
Texas
| – | -$390K | -6,000 | Closed |
|
|
BAM
256
Blueshift Asset Management
Red Bank,
New Jersey
| – | -$276K | -4,253 | Closed |
|
|
QI
257
QS Investors
New York
| – | -$235K | -3,600 | Closed |
|
|
AC
258
Allstate Corporation
Northbrook,
Illinois
| – | -$223K | -3,430 | Closed |
|
|
PFS
259
Prospera Financial Services
Dallas,
Texas
| – | -$126K | -1,943 | Closed |
|
|
SIA
260
SeaBridge Investment Advisors
Summit,
New Jersey
| – | -$20K | -300 | Closed |
|
|
AF
261
Advisornet Financial
Minnetonka,
Minnesota
| – | -$10K | -150 | Closed |
|
|
CWC
262
Carolinas Wealth Consulting
Charlotte,
North Carolina
| – | -$1K | -18 | Closed |
|
263
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
| – | +$339 | +4 | New |
|
BHVN Hedge Fund Activity: Q4 2020 in Review
238 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q4 2020, worth a combined $4.78B — up 22% from $3.9B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new BHVN positions and 26 closed out — a net gain of 24 holders — while 79 added to existing stakes and 89 trimmed.
The largest buyer was Capital World Investors, adding an estimated $114M. The largest seller was Avidity Partners Management, cutting an estimated $67.1M.
- 238 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q4 2020, up from 215 in Q3 2020.
- Funds reported $4.78B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q4 2020, up 22% quarter-over-quarter.
- 50 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q4 2020 and 26 closed out, a net change of +24 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q4 2020 was Capital World Investors, an estimated $114M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q4 2020 was Avidity Partners Management, an estimated $67.1M sold.
Based on aggregated 13F filings for Q4 2020.